AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03832244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sub-mental ultrasonography
Description: Sub-mental ultrasonography including tongue-base thickness, retropalatal distance and the distance between lingual arteries
Study NCT00312403 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Sample
Description: A single venous blood sample will be taken (10 ml).
Study NCT03204786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vasopressin (USP) Injectable Solution [Vasostrict]
Description: Nasal Spray
Study NCT03204786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin (USP) Injectable Solution [Vasostrict]
Description: Nasal Spray
Study NCT01592240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBO
Description: Placebo, Q14d
Study NCT01592240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04950615
Description: PF-04950615 50mg, Q14d
Study NCT01592240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04950615
Description: PF-04950615 100 mg, Q14d
Study NCT01592240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04950615
Description: PF-04950615 150mg, Q14d
Study NCT01298050 — intervention group
Intervention type: PROCEDURE
Intervention: ECMO
Description: Insertion of peripheral Veno-Arterious ECMO, subsequent therapeutic hypothermia
Study NCT02751437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine
Study NCT01189747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: 24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1
Study NCT01189747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Injected into bilateral Crow's Feet Line areas on Day 1
Study NCT03234127 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Whole Genome Sequencing
Description: Whole Genome Sequencing Biomarkers analyses
Study NCT00649974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valtrex® Tablets 1000 mg
Description: 1000mg, single dose fasting
Study NCT01422304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to neostigmine
Description: Normal saline (NaCl 0.9%)
Study NCT04495543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Skills for Safer Living
Description: Brief-SfSL is a single-session individual therapy adaptation of the core goals/principles of the 20-week SfSL group therapy. Brief-SfSL incorporates the SfSL guiding principles of emphasizing safety, attending to the therapeutic relationship, recognizing the participant as the expert in their own experience, taking a trauma-informed approach, working with emotions while recognizing the role of alexithymia, and incorporating solution-focused concepts. The goal is to increase a person's understanding and capacity to engage in what would enable them to keep safe, even if thoughts of suicide are present. The intervention procedure is dynamic, but includes 4 core tasks: 1) understanding the individual's suicidal experience, 2) skills building, 3) developing a safety plan, and 4) identifying obstacles to enacting or engaging with the safety plan.
Study NCT03983135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laparoscopic mini gastric by-pass
Description: Adhesions will separated along the left edge of the stomach and the left lobe of the liver. The remnant stomach will transected at the incisura angularis level with 60 mm Endo-GIA stapler(ATW 35, EthiconEndo-SurgeryInc., Cincinnati, OH, USA). Later ante-cholic distal of the Treitz ligament hadgastro-jejunal anastomosisof nearly 150 cm jejunal loop performed with 44 mm Endo-GIA stapler. Routinely, the omentum will be divided in two and omentopexy will be performed around the anastomosis. The stapler line will supported by absorbable stitches.
Study NCT03983135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LaparoscopicRe-sleeve gastrectomy
Description: Adhesions will be separated with blunt and sharp dissections, then the remnant stomach will completely freed. Due to dilated antral pouch or fundus, the remnant stomach will resect as a tube stomach between the pillory and left crus with 60 mm Endo-GIA stapler accompanied by 36F bougie.
Study NCT03983135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Ygastric bypass
Description: all adhesions will separated then after the stomach pouch will formed by the linear stapler, 100 cm of jejunum will transected from the Treitz ligament. Side-to-side gastrojejunostomy will performed for the distal jejunum with the linear stapler. The anterior face of the anastomosis will manually sutured. Proximal jejunum end hadside-to-side jejuno-jejunostomy performed 150 cm distal of the gastrojejunostomy anastomosis with linear stapler on the posterior wall and manual suturing of the anterior wall.
Study NCT00963495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clioquinol
Description: Patients will take Clioquniol at escalating doses depending on when they enter into the trial.
Study NCT01422304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to sugammadex
Description: Normal saline (NaCl 0.9%)
Study NCT04772157 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Troponin Testing
Description: Lithium heparin whole blood and plasma samples will be measured with Siemens POC High Sensitivity Troponin-I Test System.
Study NCT04467840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opaganib
Description: Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).
Study NCT04467840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).
Study NCT02369315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment (Invited entry 2012)
Description: Entry to music program offered in September 2012
Study NCT02369315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control (Invited entry 2013)
Description: Entry to music program offered in September 2013
Study NCT04436003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle and articulation chains GDS method
Description: A physiotherapy method adapting treatment to patient's terrain, or psychomorphology, using chosen techniques to balance tension between muscle chains, thus optimalizing posture and mouvement.
Study NCT04439487 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometric measurements during routine preoperative visit
Description: During routine preoperative anaesthetic visit and physical examination the following predictive test measurements are obtained by a research team member not involved in the further assessment of laryngoscopy: score in modified Mallampati test, Thyromental height, Sternomental distance, Thyromental distance, Neck circumference, Mouth opening distance
Study NCT04439487 — intervention group
Intervention type: OTHER
Intervention: Assesment of intubation parameters during induction of general anaesthesia
Description: During induction of general anaesthesia and intubation research team member not involved in obtaining anthropometric measurements notes Number of intubation attempts, Intubation time, Subjective intubation difficulty, Use of bougie and Need of technique modification.
Study NCT03044093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: The group that will get in addition to Misoprostol also Mifepristone
Study NCT02042560 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Study NCT02042560 — intervention group
Intervention type: OTHER
Intervention: Spleen samples
Study NCT00114504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: simvastatin 5-10 mg/day
Study NCT01187823 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive servo ventilation
Description: Nocturnal use of Adaptive servo ventilation
Study NCT03044093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The group that will only get Misoprostol
Study NCT01187823 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nocturnal oxygen
Description: Nocturnal use of oxygen
Study NCT03921762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with Artis Active IOLs
Description: Patients will be implanted with the Artis Active IOLs during cataract surgery
Study NCT03921762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with AT Lara IOLs
Description: Patients will be implanted with the AT Lara IOLs during cataract surgery
Study NCT01847235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle).
Study NCT03044093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Both groups will get think drug
Study NCT00937664 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AZD7762
Description: solution, intravenous, weekly
Study NCT03044093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Both groups will get think drug
Study NCT03113162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell
Study NCT03113162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEAM Regimen
Description: Reduced-intensity BEAM for Immunoablation
Study NCT03148080 — intervention group
Intervention type: PROCEDURE
Intervention: Cognitive Assessment
Description: Complete CogState
Study NCT00937664 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: gemcitabine
Description: intravenous, weekly
Study NCT03596710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image Guided Biopsy
Description: Undergo image guided biopsy
Study NCT03397719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Condition
Description: This group will receive three hours of parent coaching per week, one hour per week will involve feedback on parent usage of coached strategies based on parent recorded interactions with their children.
Study NCT03148080 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete Self-Report Questionnaire
Study NCT01608438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customizing the Body-Machine Interface
Description: The intervention compares two ways of customizing the body-machine interface which will be used for subjects for 40 sessions (spread over 8 months). In one case (SCI static), the body-machine interface is static. In the other case (SCI Machine Learning), there is a machine learning algorithm that adapts to the movements made by the subject.
Study NCT02716597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25% Albumin
Study NCT02716597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02985333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 170 mg/m(2) IV over 3 h d1
Study NCT02985333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 200mgmg/m(2) IV d1,3,5
Study NCT03112031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen will be given orally in a dose of 300mg/day for the first 14 days following randomization. It will be administered by nasogastric tube where patients are unconscious. The Tamoxifen will be administered in the morning combined with amphotericin and fluconazole dose.
Study NCT03112031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphotericin B
Description: Patients will receive amphotericin 1mg/kg/day i.v. once daily orally for the first 2 weeks.
Study NCT03112031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Description: Patients will receive amphotericin 1mg/kg/day i.v. once daily orally for the first 2 weeks.
Study NCT03112031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Patients will receive fluconazole 800mg once daily orally for the first 2 weeks. Amphotericin and fluconazole will be administered simultaneously. After the first 2 weeks of study treatment, all patients will receive fluconazole 800mg/day for 8 further weeks, until the study end.
Study NCT03112031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Patients will receive fluconazole 800mg once daily orally for the first 2 weeks. Amphotericin and fluconazole will be administered simultaneously. After the first 2 weeks of study treatment, all patients will receive fluconazole 800mg/day for 8 further weeks, until the study end.
Study NCT00591760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatotropin
Description: Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months
Study NCT02985333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20mg iv d1-4
Study NCT03397719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: This group will receive in-vivo parent coaching three hours per week.
Study NCT02161705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg) administered in paravertebral block
Study NCT02161705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Up to 0.8 mL/kg of normal saline administered
Study NCT00089583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEXIVA (GW433908)
Description: Fosamprenavir suspension or tablet bid
Study NCT02886728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily
Study NCT01131260 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: fetal STAN monitor
Description: The STAN monitor is a system for fetal surveillance that displays the FHR, the uterine activity and information resulting from the analysis of the ST segment of the fetal ECG.
Study NCT02886728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily
Study NCT01131260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fetal STAN monitor
Description: The STAN monitor is a system for fetal surveillance that displays the FHR, the uterine activity and information resulting from the analysis of the ST segment of the fetal ECG.
Study NCT01574027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: One capsule per day for six months
Study NCT02886728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily
Study NCT02886728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Capsule(s) administered orally once weekly
Study NCT02886728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: Capsule(s) administered orally once weekly
Study NCT02886728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match MTX
Description: Capsule(s) administered orally once weekly
Study NCT01574027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule per day for six months
Study NCT04132063 — intervention group
Intervention type: DRUG
Intervention: Generic levetiracetam
Description: Generic levetiracetam tablet as the same dose as original levetiracetam tablet at the switching date
Study NCT01804543 — intervention group
Intervention type: DRUG
Intervention: Ranolazine
Description: ranolazine 500 mg, then 1000 mg twice a day
Study NCT03819569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small Renal Mass Biopsy
Description: Subjects will receive a small renal mass biopsy prior to making a treatment decision
Study NCT03819569 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Small Renal Mass Biopsy
Description: Subjects will not receive a small renal mass biopsy prior to making a treatment decision
Study NCT03230955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological and psycho-educational support by phone
Description: The intervention is based on cognitive-behavioural therapy (CBT). The intervention, in order to achieve behavioural changes, will include components based in Bandura's social learning theory and social cognitive theory (Bandura, 1986) and the transtheorical model of change (Prochaska, 1992). It has been shown that expectations and self-efficacy are behavioural predictors and that they are an effective framework for the assistance to quit smoking. This theory allows evaluating patient motivation phase and adapting the interventions according to each phase (Fiore, 2011)
Study NCT03230955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief counselling session
Description: Brief counselling session
Study NCT00264043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: emboli capturing guidewire device combined with stent
Description: AngioGuard™ device and Bx Velocity™ stent
Study NCT02687386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone packaged EDV (EnGeneIC Delivery Vehicle)
Description: EnGeneIC Delivery Vehicles (EDVs) are nanocells which can be loaded with anti-cancer drugs (mitoxantrone in this study) and targeted to tumor cells. These bacterially-derived nanocells are coated in bispecific antibodies (BsAb) that recognize oncogenic receptors on the tumor cell surface. Once bound to the tumour cell, the targeted and drug-loaded EDVs are endocytosed and release their toxic payload to destroy the tumor cell.
Study NCT05439265 — intervention group
Intervention type: OTHER
Intervention: Electronic medical record order panel and resident involvement
Description: Prior to 2014, there was no formal process for evaluation of patients with HIT. In November of 2014, an EMR tool was created in an effort to improve heparin allergy documentation and HIT management. This EMR tool prompts the medical team to perform the 4T score, displays the appropriate HIT labs, alternative anticoagulation strategies, instructs the nurse to apply an allergy bracelet, and notifies the pharmacy resident through the order verification queue. The pharmacy resident then performs an independent 4T score, discontinues all heparin products, documents the heparin allergy in the medical record, and assesses the need for alternative anticoagulation.
Study NCT01273649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: cryotherapy is given with other physical training
Study NCT02116140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [C11]Acetate and HED PET
Study NCT01822028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment A
Description: Florastor® placebo. Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
Study NCT01822028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Florastor® placebo. Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
Study NCT03082586 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 1
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
Study NCT03082586 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 2
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
Study NCT03082586 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 3
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
Study NCT03082586 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 4
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
Study NCT03082586 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 5
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;
Study NCT03082586 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 6
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly